Murcia

• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 4 2024-05-14 Richter´syndrome
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 4 2024-05-13 Acute lymphoid leukemia
• First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma Recruiting
  2023-507213-97-00 1 2024-05-09 Relapsed/refractory B-cell aggressive lymphoma
• Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted a … Recruiting
  2023-508442-18-00 5 2024-04-14 Patients with an infection of the osteosynthesis material implanted af
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• Phase I/IIa multicentre study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beau … Recruiting
  2024-514544-90-00 9 2024-03-11 Relapsed or refractory B-cell lymphoma
• A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit … Recruiting
  2023-504835-42-00 4 2024-02-29 Heart Failure (Heart Failure with Reduced Ejection Fraction)
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory … Recruiting
  2023-503206-37-00 5 2023-11-20 Mantle Cell Lymphoma (MCL)
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of elacestran … Recruiting
  2023-503373-37-01 4 2023-09-11 Premenopausal women with early luminal breast cancer
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 5 2023-07-14 Acute Myeloid Leukemia
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Recruiting
  2022-502415-11-00 5 2023-06-16 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA … Recruiting
  2024-519194-19-00 7 2023-06-06 Chronic lymphocytic leukemia (CLL)
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• A Study in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment with Pozelimab + Cemdisira … Recruiting
  2023-510336-36-00 5 2023-05-05 Paroxysmal nocturnal hemoglobinuria (PNH)
• Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (A … Recruiting
  2023-503698-40-00 5 2023-03-23 Preeclampsia

Showing 169–192 of 426 trials